129 related articles for article (PubMed ID: 14567908)
1. TSH, the bone suppressing hormone.
Novack DV
Cell; 2003 Oct; 115(2):129-30. PubMed ID: 14567908
[TBL] [Abstract][Full Text] [Related]
2. TSH is a negative regulator of skeletal remodeling.
Abe E; Marians RC; Yu W; Wu XB; Ando T; Li Y; Iqbal J; Eldeiry L; Rajendren G; Blair HC; Davies TF; Zaidi M
Cell; 2003 Oct; 115(2):151-62. PubMed ID: 14567913
[TBL] [Abstract][Full Text] [Related]
3. [The cytokine system of bone tissue].
Stilgren LS; Abrahamsen B; Abdallah BM; Jørgensen NR
Ugeskr Laeger; 2005 Feb; 167(8):874-8. PubMed ID: 15789838
[No Abstract] [Full Text] [Related]
4. Genetic confirmation for a central role for TNFα in the direct action of thyroid stimulating hormone on the skeleton.
Sun L; Zhu LL; Lu P; Yuen T; Li J; Ma R; Baliram R; Moonga SS; Liu P; Zallone A; New MI; Davies TF; Zaidi M
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9891-6. PubMed ID: 23716650
[TBL] [Abstract][Full Text] [Related]
5. Physiology: Foreman in the bone factory.
Tromans A
Nature; 2003 Oct; 425(6961):909. PubMed ID: 14586451
[No Abstract] [Full Text] [Related]
6. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.
Zhang W; Zhang Y; Liu Y; Wang J; Gao L; Yu C; Yan H; Zhao J; Xu J
J Biomech; 2014 Apr; 47(6):1307-14. PubMed ID: 24629929
[TBL] [Abstract][Full Text] [Related]
7. [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism].
Stajszczyk M
Pol Arch Med Wewn; 2002 Sep; 108(3):915-24. PubMed ID: 12600190
[No Abstract] [Full Text] [Related]
8. [TSH affects bone metabolism. Surprising skeletal changes in genetically modified mice].
Lindstedt G
Lakartidningen; 2004 Feb; 101(6):476-7. PubMed ID: 15004943
[No Abstract] [Full Text] [Related]
9. Genetic regulation of osteoclast development and function.
Teitelbaum SL; Ross FP
Nat Rev Genet; 2003 Aug; 4(8):638-49. PubMed ID: 12897775
[TBL] [Abstract][Full Text] [Related]
10. Newly reported roles of thyroid-stimulating hormone and follicle-stimulating hormone in bone remodelling.
Sendak RA; Sampath TK; McPherson JM
Int Orthop; 2007 Dec; 31(6):753-7. PubMed ID: 17611756
[TBL] [Abstract][Full Text] [Related]
11. Histological evaluation for "bone quality" on two mouse models with different bone remodeling.
Amizuka N; Shimomura J; Li M; Nasu M; Maeda T
J Bone Miner Metab; 2005; 23 Suppl():43-7. PubMed ID: 15984413
[No Abstract] [Full Text] [Related]
12. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
[TBL] [Abstract][Full Text] [Related]
13. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
[TBL] [Abstract][Full Text] [Related]
14. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
[TBL] [Abstract][Full Text] [Related]
15. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin: a novel local player in bone metabolism.
Hofbauer LC; Heufelder AE
Eur J Endocrinol; 1997 Oct; 137(4):345-6. PubMed ID: 9368500
[No Abstract] [Full Text] [Related]
17. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
[TBL] [Abstract][Full Text] [Related]
19. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
20. Maturation-state dependent response of human periodontal ligament cells to an intermittent parathyroid hormone exposure in vitro.
Lossdörfer S; Stier S; Götz W; Jäger A
J Periodontal Res; 2006 Feb; 41(1):62-72. PubMed ID: 16409257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
